Skip to content

Creatine Kinase Versus 3D Doppler for Antenatal Diagnosis of Abnormal Adherent Placenta.

Creatine Kinase Versus 3D Doppler for Antenatal Diagnosis of Morbidly Adherent Placenta

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03224780
Enrollment
200
Registered
2017-07-21
Start date
2017-06-01
Completion date
2021-06-30
Last updated
2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta

Brief summary

Placenta accreta is a potentially life-threatening obstetric condition that requires a multidisciplinary approach to management.Diagnosis of placenta accreta before delivery minimizes potential maternal or neonatal morbidity and mortality. In this study the researchers will evaluate the role and cost effectiveness of biochemical marker as creatine kinase in comparison with 3D Doppler ultrasound in antenatal diagnosis of placenta accreta and its variants in patients with placenta previa totalis.

Detailed description

Abnormal placentation poses a diagnostic and treatment challenge for all providers caring for pregnant women. As one of the leading causes of postpartum hemorrhage, abnormal placentation involves the attachment of placental villi directly to the myometrium with potentially deeper invasion into the uterine wall or surrounding organs. Surgical procedures that disrupt the integrity of uterus, including cesarean section, dilatation and curettage, and myomectomy, have been implicated as key risk factors for placenta accreta(Megier et al., 2000).Prenatal diagnoses of placenta accreta through the use of gray-scale ultrasonography, color Doppler imaging, and magnetic resonance imaging have been reported previously (Chou et al., 1997). Placenta increta and percreta have rarely been diagnosed antepartum, and ultrasonographic findings may provide the only objective evidence of placenta accreta.A biochemical marker for this condition would therefore be useful (Ophir et al., 1999).It is critical to make the diagnosis before delivery because preoperative planning can significantly decrease blood loss and avoid substantial morbidity associated with placenta accreta (Shih et al., 2009).

Interventions

DIAGNOSTIC_TEST3D Doppler ultrasound

Doppler for placental vessels

DIAGNOSTIC_TESTmaternal serum creatine kinase

Biochemical marker

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

\- a- Pregnant lady with history of previous cesarean section or hysterotomy. b- Placenta previa with its lower edge covering the scar of previous cesarean section as diagnosed by 2DU/S. c- Gestational age ranging from 28 wks - Full term.

Exclusion criteria

* Women with one or more of the following conditions contributing to rhabdomyolysis: 1. Crush injury and prolonged surgery. 2. Embolism, thrombosis, D.V.T., myocardial or brain infarction. 3. Drug overdose: Antipsychotics, antidepressants, hypnotics, narcotics, alcohol, halothane,salicylates. 4. Excessive muscle activity as epileptic fit. 5. Chronic hypertension & PIH 6. Endocrine disorders: hyper-/hypothyroidism, and diabetes mellitus,history of liver disease or renal disease.

Design outcomes

Primary

MeasureTime frameDescription
maternal morbidityfrom 28 weeks gestation until 24 hours postpartum.Antepartum and Postpartum maternal complications of morbidly adherent placenta.

Countries

Egypt

Contacts

Primary ContactNesreen A Shehata
nesoomar@yahoo.com00201024150605
Backup ContactHamada Ashry Abd el Wahed
hamadaashry2010@yahoo.com01007240754

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026